Article info

Download PDFPDF
ICON 9—an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy

Authors

  1. Correspondence to Dr Osnat Elyashiv, University College CRUK and UCL Cancer Trials Centre, UCL Cancer Institute, London WC1E 6DD, UK; osnatelyashiv{at}gmail.com
View Full Text

Citation

Elyashiv O, Ledermann J, Parmar G, et al
ICON 9—an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy

Publication history

  • Accepted October 6, 2020
  • First published October 23, 2020.
Online issue publication 
January 04, 2021

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.